Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered into a strategic partnership with Hopstem Biotechnology Co., Ltd, a neural stem cell specialist founded by a team of neuroscientists and stem-cell biologists from Johns Hopkins University. The collaboration aims to enhance the quality and safety detection of cell therapy products, marking a significant step forward in the field. Financial details of the agreement were not disclosed.
Hopstem, a pioneer in the development of induced pluripotent stem cell (iPSC) therapies in China, is known for its iPSC-derived hNPC01, a treatment for the sequelae of hemiplegia following ischemic stroke. This product is not only the first neurological iPSC cell product in China to receive clinical approval from the Center for Drug Evaluation (CDE), but it also holds the distinction of being the world’s first pluripotent stem cell-derived forebrain precursor cell product approved for clinical use. Suzhou Jade Biomedical is proud to announce its partnership with Charles River, which will provide a comprehensive suite of Chinese, American, and European standard release tests for iPSC master cell banks and working cell banks.- Flcube.com
